Please login to the form below
academia
This page shows the latest academia news and features for those working in and with pharma, biotech and healthcare.
Is competition the enemy of progress and collaboration the ally of success?
What exactly do I mean by collaboration? Collaboration with academia to elevate research capabilities.
Latest news
-
Novartis and Sanofi heads take on UK pharma leadership roles
world. “In the current Brexit environment, it is more important than ever to collaborate across government, businesses and academia to ensure that the UK can maintain its position as a leader
-
UCB looks to pipeline with five years left for twin blockbusters
drug discovery partnership with King’s College London university and its research teams working across academia and the NHS.
-
Merck & Co to buy IO specialists Immune Design for $300m
Big pharma, biotech and academia are zeroing in on a range of immune system mechanisms which could prove crucial to fighting diverse diseases.
-
UCB signs research deal with King’s College London
our world class expertise in translational research and clinical development at King’s with UCB’s long and successful track record of partnering with UK academia will yield successful benefits for
-
A genomics and digital-led NHS is possible – but investment in staff essential
It is logical that progress in meeting these challenges will be most effectively addressed through collaboration across industry, NHS and academia.
More from news
Approximately 7 fully matching, plus 135 partially matching documents found.
Latest Intelligence
-
Integrating electronic health records into clinical trials
At the Leveraging EHR for Clinical Research Now! event, leaders from academia, companies including Amgen and AstraZeneca and the US Food and Drug Administration sought to identify the factors that are
-
Driving the innovation engine
It means reaching out to industry, academia and government partnerships, upping the scope for the generation of novel approaches and reducing the investment required to develop ideas. ... If anything, links to academia have become ever more important and
-
Changing direction: adapting to a rapidly-evolving environment
This means building long-term partnerships with a diverse range of stakeholders – patients, clinicians, scientists, consumers, tech companies, data scientists, academia and communicators – to identify genuine unmet need and co-create
-
Building European biotech firms to rival those of the US
There is so much academia, entrepreneurship and innovation on this axis, and creating those links would have long-term benefits for cross fertilisation of ideas and economic mobility in the country. ... I think it’s probably more daunting for people to
-
European biotech: a new generation of leaders emerges
We believe that it will [also] increase Genmab’s visibility as a world class innovation powerhouse within the biotech industry and among key thought leaders and academia and in the financial
More from intelligence
Approximately 1 fully matching, plus 39 partially matching documents found.
Latest appointments
-
New hires at Nanoform, Leo Pharma and Calliditas
Sandler comes to Nanoform with extensive experience in both industry and academia, particularly in pharmaceutical product development and material science.
-
Kevin Sin joins GSK
Gaining access to the best science and technologies across the world as well as establishing highly productive collaborations with academia and industry, play an important role in creating a world-class
-
Professor Carole Longson moves from NICE to the ABPI
experience, expertise and network in both industry and academia will enable the ABPI to work with our partners to further these objectives.”.
-
Orion appoints VP of oncology, R&D
I hope that my long background in the academia will help in the initiation of new research projects between Orion and the academia.
-
Storm Therapeutics strengthens its board
I look forward to working with the board to help guide Storm’s innovative research programmes, adding my experience from drug discovery in academia, pharma and biotech.”.
More from appointments
Approximately 1 fully matching, plus 18 partially matching documents found.
Latest from PMHub
-
Cello Health launches ‘Cello Health GmbH’ with new Berlin office and appointment of two regional directors to lead the Business Insights and Analytics division in Germany.
companies as well as associated industries and academia.
-
Porterhouse Medical Group strengthens its US scientific team
His excellent heritage from academia, through agency, then pharma and back to the consulting and agency world – means that he has an excellent appreciation of client needs and how best an
-
The problem with the ‘recovery’ conversation in mental health
The narrative widely told in both the media and in academia typically describes an individual who has ‘recovered’ from a one-off episode of depression at some point in the past.
-
Random42 Partner with MedCity for BioJapan 2018
Random42 have partnered with MedCity to attend the event as part of the UK delegation, which aims to showcase the UK’s ecosystem and forge collaborations with Japanese pharma and academia. ... We facilitate connectivity across industry, academia
-
Pegasus opens health track at Cannes Lions
Hehir, showing that the seemingly very different worlds of creative agencies and academia can come together to embed behaviour change theory into the creative process.
More from PMHub
Approximately 0 fully matching, plus 26 partially matching documents found.
Featured jobs
- Senior Medical Writer, MedComms Agency
-
Salary TBC
- Account Director or Senior Account Director
-
Salary TBC
- Account Director, Medical Communications & Events
-
£50 - 65, 000 according to skills and experience benefits
- Director of Scientific Services, Medical Communications, Six fig...
-
Six figure salary
-
Consultant
-
competitive salary
-
Vice President
-
Competitive Salary Offered
-
Principal Medical Writer
-
£48 - 58, 000 according to skills and experience benefits
- Account Manager– Medical Communications
-
(Negotiable - depending on experience)
Subscribe to our email news alerts
- Lilly will aim for one $1bn-$5bn deal per quarter in 2020
- Novartis gets EU approval for multiple sclerosis therapy Mayzent
- Immuno-oncology, personalised medicine continues to drive pharma sector
- NICE leaves the ‘the NHS door’ open despite rejecting Bayer’s Vitrakvi
- FDA delays decision on Intercept's NASH drug by three months
- Novartis gets EU approval for multiple sclerosis therapy Mayzent
- New coronavirus sees drug developers scramble to develop a vaccine
- Sanofi completes acquisition of immuno-oncology specialist Synthorx
- Roche's checkpoint inhibitor fails pivotal urothelial cancer trial
- Epizyme wins FDA approval for epithelioid sarcoma treatment
- Pharma Brand Planners' Blog (Part 8)
- Happy Chinese New Year 2020 - The Year of The Rat
PMHub
CSafe Global
CSafe Global is the only global provider of a full line of cold chain solutions and is the world’s largest...
Latest intelligence
- Happy Chinese New Year 2020 - The Year of The Rat
- A fond farewell to The Year of the Pig...
- White Paper for download - Explaining the price of your product
- In this white paper, he breaks down the pricing options available to you, shares stories from his extensive experiences, and talks you through how to better define your pricing, step-by-step....
- OPEN Health expands offering with the launch of a new Learning & Development specialist team
- Enhanced expertise to deliver impactful internal training programmes for healthcare clients...
Quick links
Infographics
